Exelixis
EXEL
#1694
Rank
โ‚น1.072 T
Marketcap
โ‚น3,985
Share price
-0.02%
Change (1 day)
30.57%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Revenue for Exelixis (EXEL)

Revenue in 2025 (TTM): โ‚น197.90 Billion

According to Exelixis's latest financial reports the company's current revenue (TTM ) is โ‚น205.56 Billion. In 2024 the company made a revenue of โ‚น186.04 Billion an increase over the revenue in the year 2023 that were of โ‚น152.36 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Exelixis from 2000 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) โ‚น197.90 B6.37%
2024 โ‚น186.04 B22.11%
2023 โ‚น152.36 B14.29%
2022 โ‚น133.31 B24.82%
2021 โ‚น106.80 B47.89%
2020 โ‚น72.22 B4.65%
2019 โ‚น69.01 B15.6%
2018 โ‚น59.70 B106.64%
2017 โ‚น28.89 B122.06%
2016 โ‚น13.01 B426.67%
2015 โ‚น2.47 B55.22%
2014 โ‚น1.59 B-17.8%
2013 โ‚น1.93 B-25.48%
2012 โ‚น2.59 B-83.04%
2011 โ‚น15.32 B84.78%
2010 โ‚น8.29 B17.76%
2009 โ‚น7.04 B24.3%
2008 โ‚น5.66 B27.21%
2007 โ‚น4.45 B1.9%
2006 โ‚น4.37 B27.85%
2005 โ‚น3.41 B49.33%
2004 โ‚น2.28 B-2.45%
2003 โ‚น2.34 B10.41%
2002 โ‚น2.12 B7.42%
2001 โ‚น1.97 B71.23%
2000 โ‚น1.15 B

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
GlaxoSmithKline
GSK
โ‚น3.804 T 1,750.91%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sanofi
SNY
โ‚น4.269 T 1,976.95%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
โ‚น5.770 T 2,707.21%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚น4.315 T 1,999.19%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
โ‚น3.231 T 1,472.01%๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
โ‚น8.278 T 3,927.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
โ‚น5.640 T 2,643.88%๐Ÿ‡บ๐Ÿ‡ธ USA
Curis
CRIS
โ‚น1.04 B-99.49%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
โ‚น8.47 B-95.88%๐Ÿ‡บ๐Ÿ‡ธ USA